Home › Head and Neck Squamous Cell Carcinoma › Delaware › Newark
Head and Neck Squamous Cell Carcinoma clinical trials in Newark, DE
3 studies for Head and Neck Squamous Cell Carcinoma are looking for participants at sites in and around Newark (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
RecruitingPhase 2/3
- ChristianaCare Helen F. Graham Cancer Center and Research Institute (Site # 127), Newark
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
RecruitingPhase 2
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
RecruitingPhase 3
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
- Christiana Care Health System-Christiana Hospital, Newark
Head and Neck Squamous Cell Carcinoma trials in other cities
- Houston, TX47 studies
- Los Angeles, CA42 studies
- Boston, MA40 studies
- Nashville, TN39 studies
- New York City, NY39 studies
- St. Louis, MO28 studies
- Arlington, VA26 studies
- Philadelphia, PA26 studies
- Chicago, IL26 studies
- Atlanta, GA24 studies
- Pittsburgh, PA22 studies
- New Haven, CT22 studies
Other studies in Newark
- Non-Small Cell Lung Cancer16 studies
- Prostate Cancer10 studies
- Colorectal Cancer9 studies
- Lung Cancer9 studies
- Breast Cancer8 studies
- Metastatic Cancer7 studies
- Cancer (all types)6 studies
- Pancreatic Cancer6 studies
- Ovarian Cancer5 studies
- Follicular Lymphoma4 studies
- Chronic Lymphocytic Leukemia4 studies
- Stomach Cancer4 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.